New drug formulation tested to make lymphoma transplants safer
NCT ID NCT06915246
Summary
This study is testing whether a new formulation of the chemotherapy drug carmustine causes fewer side effects than the standard version when used as part of the high-dose chemotherapy given before a stem cell transplant. The trial will enroll about 49 adults with Hodgkin or non-Hodgkin lymphoma who are eligible for a transplant. Researchers will compare the safety and toxicity of the two drug versions to see if the new one is better tolerated.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
City of Hope Atlanta
RECRUITINGNewnan, Georgia, 30265, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
City of Hope Chicago
RECRUITINGZion, Illinois, 60099, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
City of Hope National Medical Center
RECRUITINGDuarte, California, 91010, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
City of Hope Phoenix
RECRUITINGGoodyear, Arizona, 85338, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.